Cost-Consciousness Raising: Adding Value To Cancer Drug Development
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
As the market attempts to reconcile the high prices of revolutionary new cancer therapies with pressure to control rising health care costs, oncology associations call for new drugs to demonstrate clinical value in addition to meeting FDA’s standards of safety and efficacy. Can “continuous learning systems” help?